Mycofenolaat Mofetil Stada (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mycofenolaat Mofetil Stada, is an antimetabolite immunosuppressant presented as an oral formulation for oral use. It is employed to prevent organ transplant rejection by selectively inhibiting lymphocyte proliferation in transplant recipients. The drug is indicated for adult patients undergoing kidney, liver or heart transplantation and is administered under medical supervision.

GNH USA supplies Mycofenolaat Mofetil Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. All batches are manufactured in accordance with EU GMP guidelines and undergo rigorous quality testing before release.

Mycophenolate Mofetil is used as an immunosuppressive agent to reduce the risk of rejection in solid‑organ transplantation.

- Kidney transplant: helps prevent graft rejection by suppressing lymphocyte activity. - Liver transplant: reduces incidence of acute rejection episodes. - Heart transplant: maintains graft function by inhibiting immune response.

Adverse reactions may occur with Mycophenolate Mofetil therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools. - Headache: transient cranial discomfort. - Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects: - Opportunistic infections: increased susceptibility to viral, fungal or bacterial pathogens. - Malignancy: heightened risk of post‑transplant lymphoproliferative disorder. - Severe anemia: marked reduction in hemoglobin levels. - Hepatic toxicity: elevated liver enzymes or hepatitis.

Patients receiving Mycophenolate Mofetil should be monitored closely for safety.

- Monitor blood counts: perform regular CBC to detect leukopenia or anemia. - Assess renal function: adjust therapy if creatinine clearance declines. - Avoid active infection: treat infections before initiating therapy. - Pregnancy: contraindicated unless benefits outweigh risks; discuss contraception. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Mycophenolate Mofetil may interact with several concomitant medicines.

Major Interactions (Avoid): - Cyclosporine: increased nephrotoxicity risk. - Tacrolimus: heightened mycophenolate exposure. - Live vaccines: risk of severe infection; avoid administration.

Moderate Interactions (Monitor Closely): - Azathioprine: additive bone‑marrow suppression. - Rifampin: may lower mycophenolate plasma levels. - Warfarin: potential increase in INR, monitor coagulation.